07:04 AM EST, 11/14/2025 (MT Newswires) -- Sanofi ( SNY ) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the therapy Teizeild for delaying the onset of stage 3 type 1 diabetes in adult and pediatric patients eight years of age and older with stage 2 type 1 diabetes.

The opinion was supported by data from a phase 2 clinical study, which the company said demonstrated that Teizeild significantly delayed the onset of stage 3 type 1 diabetes by a median of about two years compared to placebo.